Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions

Finbarr O'Harte, Vadivel Parthsarathy, C Hogg, Peter Flatt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nine structurally modified apelin-13 analogues were assessed for their in vitro and acute in vivo antidiabetic potential. Stability was assessed in mouse plasma and insulinotropic efficacy tested in cultured pancreatic BRIN-BD11 cells and isolated mouse pancreatic islets. Intracellular Ca2+ and cAMP production in BRIN-BD11 cells was determined, as was glucose uptake in 3T3-L1 adipocytes. Acute antihyperglycemic effects of apelin analogues were assessed following i.p. glucose tolerance tests (ipGGT, 18 mmol/kg) in normal and diet-induced-obese (DIO) mice and on food intake in normal mice. Apelin analogues all showed enhanced in vitro stability (up to 5.8-fold, t½ = 12.8 h) in mouse plasma compared to native apelin-13 (t½ = 2.1 h). Compared to glucose controls, stable analogues exhibited enhanced insulinotropic responses from BRIN-BD11 cells (up to 4.7-fold, p <0.001) and isolated mouse islets (up to 5.3-fold) for 10−7 M apelin-13 amide (versus 7.6-fold for 10−7 M GLP-1). Activation of APJ receptors on BRIN-BD11 cells increased intracellular Ca2+ (up to 3.0-fold, p <0.001) and cAMP (up to 1.7-fold, p <0.01). Acute ipGTT showed improved insulinotropic and glucose disposal responses in normal and DIO mice (p <0.05 and p <0.01, respectively). Apelin-13 amide and (pGlu)apelin-13 amide were the most effective analogues exhibiting acute, dose-dependent and persistent biological actions. Both analogues stimulated insulin-independent glucose uptake by differentiated adipocytes (2.9 to –3.3-fold, p <0.05) and inhibited food intake (26-–33%, p <0.001), up to 180 min in mice, versus saline. In contrast, (Ala13)apelin-13 and (Val13)apelin-13 inhibited insulin secretion, suppressed beta-cell signal transduction and stimulated food intake in mice. Thus, stable analogues of apelin-13 have potential for diabetes/obesity therapy.
LanguageEnglish
Pages219-228
JournalPeptides
Volume100
Early online date3 Feb 2018
DOIs
Publication statusE-pub ahead of print - 3 Feb 2018

Fingerprint

Glucose
Amides
Obese Mice
Eating
Nutrition
Hypoglycemic Agents
Adipocytes
Insulin
Diet
Plasmas
Signal transduction
Glucagon-Like Peptide 1
apelin-13 peptide
In Vitro Techniques
Glucose Tolerance Test
Medical problems
Islets of Langerhans
Signal Transduction
Obesity
Chemical activation

Keywords

  • Apelin-13 analogues
  • Diabetes
  • insulin secretion
  • Glucose homeostasis

Cite this

@article{b0259d888ef248048909abddf15adfd8,
title = "Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions",
abstract = "Nine structurally modified apelin-13 analogues were assessed for their in vitro and acute in vivo antidiabetic potential. Stability was assessed in mouse plasma and insulinotropic efficacy tested in cultured pancreatic BRIN-BD11 cells and isolated mouse pancreatic islets. Intracellular Ca2+ and cAMP production in BRIN-BD11 cells was determined, as was glucose uptake in 3T3-L1 adipocytes. Acute antihyperglycemic effects of apelin analogues were assessed following i.p. glucose tolerance tests (ipGGT, 18 mmol/kg) in normal and diet-induced-obese (DIO) mice and on food intake in normal mice. Apelin analogues all showed enhanced in vitro stability (up to 5.8-fold, t½ = 12.8 h) in mouse plasma compared to native apelin-13 (t½ = 2.1 h). Compared to glucose controls, stable analogues exhibited enhanced insulinotropic responses from BRIN-BD11 cells (up to 4.7-fold, p <0.001) and isolated mouse islets (up to 5.3-fold) for 10−7 M apelin-13 amide (versus 7.6-fold for 10−7 M GLP-1). Activation of APJ receptors on BRIN-BD11 cells increased intracellular Ca2+ (up to 3.0-fold, p <0.001) and cAMP (up to 1.7-fold, p <0.01). Acute ipGTT showed improved insulinotropic and glucose disposal responses in normal and DIO mice (p <0.05 and p <0.01, respectively). Apelin-13 amide and (pGlu)apelin-13 amide were the most effective analogues exhibiting acute, dose-dependent and persistent biological actions. Both analogues stimulated insulin-independent glucose uptake by differentiated adipocytes (2.9 to –3.3-fold, p <0.05) and inhibited food intake (26-–33{\%}, p <0.001), up to 180 min in mice, versus saline. In contrast, (Ala13)apelin-13 and (Val13)apelin-13 inhibited insulin secretion, suppressed beta-cell signal transduction and stimulated food intake in mice. Thus, stable analogues of apelin-13 have potential for diabetes/obesity therapy.",
keywords = "Apelin-13 analogues, Diabetes, insulin secretion, Glucose homeostasis",
author = "Finbarr O'Harte and Vadivel Parthsarathy and C Hogg and Peter Flatt",
year = "2018",
month = "2",
day = "3",
doi = "10.1016/j.peptides.2017.12.004",
language = "English",
volume = "100",
pages = "219--228",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions. / O'Harte, Finbarr; Parthsarathy, Vadivel; Hogg, C; Flatt, Peter.

In: Peptides, Vol. 100, 03.02.2018, p. 219-228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions

AU - O'Harte, Finbarr

AU - Parthsarathy, Vadivel

AU - Hogg, C

AU - Flatt, Peter

PY - 2018/2/3

Y1 - 2018/2/3

N2 - Nine structurally modified apelin-13 analogues were assessed for their in vitro and acute in vivo antidiabetic potential. Stability was assessed in mouse plasma and insulinotropic efficacy tested in cultured pancreatic BRIN-BD11 cells and isolated mouse pancreatic islets. Intracellular Ca2+ and cAMP production in BRIN-BD11 cells was determined, as was glucose uptake in 3T3-L1 adipocytes. Acute antihyperglycemic effects of apelin analogues were assessed following i.p. glucose tolerance tests (ipGGT, 18 mmol/kg) in normal and diet-induced-obese (DIO) mice and on food intake in normal mice. Apelin analogues all showed enhanced in vitro stability (up to 5.8-fold, t½ = 12.8 h) in mouse plasma compared to native apelin-13 (t½ = 2.1 h). Compared to glucose controls, stable analogues exhibited enhanced insulinotropic responses from BRIN-BD11 cells (up to 4.7-fold, p <0.001) and isolated mouse islets (up to 5.3-fold) for 10−7 M apelin-13 amide (versus 7.6-fold for 10−7 M GLP-1). Activation of APJ receptors on BRIN-BD11 cells increased intracellular Ca2+ (up to 3.0-fold, p <0.001) and cAMP (up to 1.7-fold, p <0.01). Acute ipGTT showed improved insulinotropic and glucose disposal responses in normal and DIO mice (p <0.05 and p <0.01, respectively). Apelin-13 amide and (pGlu)apelin-13 amide were the most effective analogues exhibiting acute, dose-dependent and persistent biological actions. Both analogues stimulated insulin-independent glucose uptake by differentiated adipocytes (2.9 to –3.3-fold, p <0.05) and inhibited food intake (26-–33%, p <0.001), up to 180 min in mice, versus saline. In contrast, (Ala13)apelin-13 and (Val13)apelin-13 inhibited insulin secretion, suppressed beta-cell signal transduction and stimulated food intake in mice. Thus, stable analogues of apelin-13 have potential for diabetes/obesity therapy.

AB - Nine structurally modified apelin-13 analogues were assessed for their in vitro and acute in vivo antidiabetic potential. Stability was assessed in mouse plasma and insulinotropic efficacy tested in cultured pancreatic BRIN-BD11 cells and isolated mouse pancreatic islets. Intracellular Ca2+ and cAMP production in BRIN-BD11 cells was determined, as was glucose uptake in 3T3-L1 adipocytes. Acute antihyperglycemic effects of apelin analogues were assessed following i.p. glucose tolerance tests (ipGGT, 18 mmol/kg) in normal and diet-induced-obese (DIO) mice and on food intake in normal mice. Apelin analogues all showed enhanced in vitro stability (up to 5.8-fold, t½ = 12.8 h) in mouse plasma compared to native apelin-13 (t½ = 2.1 h). Compared to glucose controls, stable analogues exhibited enhanced insulinotropic responses from BRIN-BD11 cells (up to 4.7-fold, p <0.001) and isolated mouse islets (up to 5.3-fold) for 10−7 M apelin-13 amide (versus 7.6-fold for 10−7 M GLP-1). Activation of APJ receptors on BRIN-BD11 cells increased intracellular Ca2+ (up to 3.0-fold, p <0.001) and cAMP (up to 1.7-fold, p <0.01). Acute ipGTT showed improved insulinotropic and glucose disposal responses in normal and DIO mice (p <0.05 and p <0.01, respectively). Apelin-13 amide and (pGlu)apelin-13 amide were the most effective analogues exhibiting acute, dose-dependent and persistent biological actions. Both analogues stimulated insulin-independent glucose uptake by differentiated adipocytes (2.9 to –3.3-fold, p <0.05) and inhibited food intake (26-–33%, p <0.001), up to 180 min in mice, versus saline. In contrast, (Ala13)apelin-13 and (Val13)apelin-13 inhibited insulin secretion, suppressed beta-cell signal transduction and stimulated food intake in mice. Thus, stable analogues of apelin-13 have potential for diabetes/obesity therapy.

KW - Apelin-13 analogues

KW - Diabetes

KW - insulin secretion

KW - Glucose homeostasis

U2 - 10.1016/j.peptides.2017.12.004

DO - 10.1016/j.peptides.2017.12.004

M3 - Article

VL - 100

SP - 219

EP - 228

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -